Previous 10 | Next 10 |
Media Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced t...
Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today annou...
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab (BAVENCIO®) Expansion into urothelial cancer builds on core strategy to in...
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash reb...
Media Release O verall response rate (ORR) increase s to 40.4% , according to iRECIS T, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer ( 1L NSCLC) ORR improved across all ...
Media Release First activity evaluat ion of efti as part of triple combination therapy yields p romising early results with 72.7% response rate and 90.9 % disease control rate in 1 st l ine N...
Immutep ( NASDAQ: IMMP ) said it was granted two patents (numbers 7160345 and 10-2441425) by the Japanese Patent Office and South Korean Patent Office, respectively. The patents titled 'Combined Preparations for the Treatment of Cancer' protects intellec...
Media Release SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is...
Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to h ost Webcast on Thursday, 10 th November at 5 PM ET to d ...
Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, tod...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...